Alava’s consultants have pioneered groundbreaking technologies that are now an important part of medical practice. Recently, major advances in cellular and gene therapies have led to increased venture funding and corporate partnerships, and demonstrated the potential for a new wave of lifesaving treatments.
Alava’s project list includes multiple CIRM-funded cellular therapy projects, nucleic acid based therapies, and diligence on inlicensing and acquisition opportunities (including a diligence project for a top pharmaceutical company). Alava team members have strong experience working with academic/medical centers, navigating the Quality expectations for novel therapies, and managing the scale-out issues connected with autologous therapies. Their deep experience with viral-based manufacturing includes vaccine platforms, oncolytic viruses and gene therapy vectors.